Centessa Pharmaceuticals (NASDAQ:CNTA) is a top up-and-coming stock to buy, with Needham raising its price target to $38 and Oppenheimer designating it a top pick due to its pipeline of orexin agonists. The firm expects stock momentum to continue through 2026 and anticipates significant clinical data readouts in the coming years.

In Q3 2025, Centessa’s lead candidate, ORX750, showed promising efficacy for treating narcolepsy. The company is set for a major clinical expansion in Q1 2026, with plans to launch the ORX750 registrational program and initiate studies for other potent agonists. Centessa is a clinical-stage pharmaceutical company focused on discovering and developing medicines.

While CNTA has investment potential, some AI stocks may offer greater upside with less risk. For those seeking an undervalued AI stock with potential benefits from tariffs and onshoring trends, consider the best short-term AI stock. Explore other stock options that could double in 3 years or hidden AI stocks to buy now. This article is from Insider Monkey.

Read more at Yahoo Finance: Needham Hikes Centessa (CNTA) PT to $38 on High Potential for ORX-750 Trial Success and M&A Appeal